ライフサイエンスコーパス: dihydroxyphenylalanine

1 mulating hormone, 8-methoxypsoralen, and 3,4-dihydroxyphenylalanine).

2 ryloxy radical coupling to form di-DOPA (3,4-dihydroxyphenylalanine).

3 cts were seen on the binding of dopamine and dihydroxyphenylalanine.

4 ctly unusual ones, 6-bromotryptophan and 3,4-dihydroxyphenylalanine.

5 tyrosine and to a lesser extent against 3,4-dihydroxyphenylalanine.

6 e catalyzes the hydroxylation of tyrosine to dihydroxyphenylalanine.

7 erial phospho-tyrosines to protein-bound 3,4-dihydroxyphenylalanine.

8 PD and following the treatment of drug l-3,4-dihydroxyphenylalanine.

9 otor deficits that can be rescued with L-3,4 dihydroxyphenylalanine.

10 re not related to melanin formation from 3,4-dihydroxyphenylalanine.

11 alyzes the hydroxylation of tyrosine to form dihydroxyphenylalanine.

12 6-(18)F-fluoro-l-3,4-dihydroxyphenylalanine ((18)F-DOPA) PET is a useful tool

13 arison with conventional imaging and (18)F-l-dihydroxyphenylalanine ((18)F-DOPA) PET/CT.

14 ion, and prognostic value of fused (18)F-3,4-dihydroxyphenylalanine ((18)F-DOPA) PET/MR images in ped

15 etaiodobenzylguanidine, 6-(18)F-fluoro-l-3,4-dihydroxyphenylalanine, (18)F-FDG, and (68)Ga-DOTA-somat

16 on of protein-bound 3-nitrotyrosine and 3, 4-dihydroxyphenylalanine (3-hydroxytyrosine) as specific i

17 for morphine when given either caffeine or l-dihydroxyphenylalanine (a dopamine precursor that restor

18 It was able to block the L-3,4-dihydroxyphenylalanine accumulation produced by CI-1017,

19 )methyl]chromen-2-one, increased DOPA (L-3,4-dihydroxyphenylalanine) accumulation 51% in the hippocam

20 he incorporation of the amino acid DOPA (3,4-dihydroxyphenylalanine) allows the self-assembled nanofi

21 lly, we revealed that the synthesis of L-3,4-dihydroxyphenylalanine, an important metabolite of L-tyr

22 strated by rescue of the dysfunction by 3, 4-dihydroxyphenylalanine and considerable dopaminergic-neu

23 teriovenous increments in plasma levels of L-dihydroxyphenylalanine and dihydroxyphenylglycol did not

24 )H-norepinephrine, and cardiac production of dihydroxyphenylalanine and measurement of left ventricul

25 L-3,4-dihydroxyphenylalanine and reserpine have been used to i

26 scopy have been used to determine that l-3,4-dihydroxyphenylalanine and reserpine increase and decrea

27 alpha-melanocyte-stimulating hormone and 3,4-dihydroxyphenylalanine) and inhibitors (hydroquinone, ar

28 ndance and proximity of catecholic Dopa (3,4-dihydroxyphenylalanine) and lysine residues hint at a sy

29 ecursor and Parkinson's therapy agent, L-3,4-dihydroxyphenylalanine, and at cell clusters incubated w

30 ed natriuresis and diuresis in response to l-dihydroxyphenylalanine, and decreased medullary COX-2 ex

31 ncreased plasma NE, epinephrine (EPI), DHPG, dihydroxyphenylalanine, and DOPAC levels by 4.3, 7.3, 2.

32 Dopamine (DA), its precursor 3,4-dihydroxyphenylalanine, and metabolite 3,4-dihydroxyphen

33 norepinephrine, normal cardiac production of dihydroxyphenylalanine, and normal myocardial 6-[(18)F]f

34 rrioxamine, indicating that cytosolic DA and dihydroxyphenylalanine are oxidized by iron-mediated cat

35 Trp > norleucine > Phe, Leu > Ile > His >3,4-dihydroxyphenylalanine, Arg > Val > Lys, Tyr, Pro > hydr

36 ment with a norepinephrine precursors (l-3,4-dihydroxyphenylalanine at 100 mg/kg or l-threo-dihydroxy

37 t to allow phenylalanine hydroxylase to form dihydroxyphenylalanine at rates comparable to that of ty

38 catalyzes the oxidation of serotonin and 3,4-dihydroxyphenylalanine by H(2)O(2).

39 modified to either tyrosine hydroperoxide or dihydroxyphenylalanine by O(2)(*-) and HO(*), respective

40 The specific activities for formation of dihydroxyphenylalanine by the S395A, S395T, and S396A en

41 enic enzymes include Tyrp1 (or TRP1) and 3,4-dihydroxyphenylalanine-chrome tautomerase (Dct or TRP2)

42 The average concentration of di-dihydroxyphenylalanine cross-links in byssal plaques is

43 ed significantly enhanced levels of 5, 5'-di-dihydroxyphenylalanine cross-links.

44 The D stereoisomer of dihydroxyphenylalanine (D-DOPA) and its alpha-keto acid

45 e utilized monoamine oxidase (MAO) and L-3,4-dihydroxyphenylalanine decarboxylase (DDC) for microbe-b

46 Aspartate 1-decarboxylase (ADC) and 3,4-dihydroxyphenylalanine decarboxylase (DDC) provide beta-

47 a new member of the opium poppy tyrosine/3,4-dihydroxyphenylalanine decarboxylase gene family (TyDC5)

48 identity with other opium poppy tyrosine/3,4-dihydroxyphenylalanine decarboxylases (84%), and when ex

49 These results support the use of L-3, 4-dihydroxyphenylalanine derivatives of PEI in any attempt

50 The high content of 3,4-dihydroxyphenylalanine (Dopa) (~30 mol %) and its locali

51 striatum (ST; 80.3% of F344) and lower basal dihydroxyphenylalanine (DOPA) accumulation after m-hydro

52 a 5-HT(1A) receptor agonist, decreased l-3,4-dihydroxyphenylalanine (DOPA) accumulation in rat striat

53 TH synthesis rate was measured by dihydroxyphenylalanine (DOPA) accumulation in the presen

54 loped for enantiomeric quantification of 3,4-dihydroxyphenylalanine (DOPA) and its precursors, phenyl

55 achieve enantioselective recognition of 3,4-dihydroxyphenylalanine (DOPA) based on a new mechanism,

56 cuticle of byssal threads given its high 3,4-dihydroxyphenylalanine (Dopa) content at 10-15 mol %.

57 omitantly, GBL treatment [along with the 3,4-dihydroxyphenylalanine (dopa) decarboxylase inhibitor NS

58 ring dopamine synthesis (accumulation of 3,4-dihydroxyphenylalanine (DOPA) following decarboxylase in

59 residue of alpha-factor was replaced by 3,4-dihydroxyphenylalanine (DOPA) for periodate-mediated che

60 etaine) (pCB) and four surface-binding l-3,4-dihydroxyphenylalanine (DOPA) groups, pCB-(DOPA)4, were

61 Dihydroxyphenylalanine (DOPA) histochemistry demonstrate

62 The interaction between a 3,4-dihydroxyphenylalanine (DOPA) labeled analogue of the tr

63 chemically defined minimal medium with L-3,4-dihydroxyphenylalanine (DOPA) or (-)-epinephrine produce

64 to evaluate the diagnostic role of (18)F-3,4-dihydroxyphenylalanine (DOPA) PET/CT at the time of stag

65 stinct EPR spectrum consistent with a stable dihydroxyphenylalanine (DOPA) radical.

66 3, 4-Dihydroxyphenylalanine (Dopa) residues in Mfps mediate b

67 KM values for substrates, the Vmax value for dihydroxyphenylalanine (DOPA) synthesis, and the couplin

68 catalyzes oxygen-dependent conversion of 3,4-dihydroxyphenylalanine (dopa) to 3,4-dihydroxyphenylacet

69 d nonenzymatically to the DA precursor l-3,4-dihydroxyphenylalanine (DOPA) under pro-oxidant conditio

70 the cross-linking of proteins containing 3,4-dihydroxyphenylalanine (DOPA) used by shellfish for stic

71 ng sequences in polypeptides to peptidyl 3,4-dihydroxyphenylalanine (DOPA) using mushroom tyrosinase

72 and phenylalanine (PHE) to the synthesis of dihydroxyphenylalanine (DOPA) were studied in PC12 cells

73 These differences result from dihydroxyphenylalanine (DOPA), a melanin precursor synth

74 exploits the adhesive characteristics of 3,4-dihydroxyphenylalanine (DOPA), an important component of

75 Fava beans (Vicia faba) contain dihydroxyphenylalanine (dopa), and their ingestion may i

76 tive against tyrosine, phenylalanine and 3,4-dihydroxyphenylalanine (dopa), tdc1 was developmentally

77 pectinata foot protein-1, apfp-1) with L-3,4-dihydroxyphenylalanine (DOPA)-containing and mannose-bin

78 As the first of the 3,4-dihydroxyphenylalanine (Dopa)-containing byssal precurso

79 We found that only l-3,4-dihydroxyphenylalanine (DOPA)-containing peptides were s

80 We previously reported l-3,4-dihydroxyphenylalanine (dopa)-histidine (dopa-His) as an

81 le animal models of PD fail to display l-3,4-dihydroxyphenylalanine (DOPA)-responsive parkinsonism an

82 xpressed by the selective recognition of 3,4-dihydroxyphenylalanine (DOPA).

83 that catalyzes the conversion of tyrosine to dihydroxyphenylalanine (DOPA).

84 trans-2,3-cis-3,4-dihydroxyproline, and 3,4-dihydroxyphenylalanine (Dopa).

85 transferase (PST), SULT1A3, has a unique 3,4-dihydroxyphenylalanine (Dopa)/tyrosine-sulfating activit

86 the pancreas itself has a high dopamine [and dihydroxyphenylalanine (dopa)] content that does not cha

87 rgy between flanking lysine (Lys, K) and 3,4-Dihydroxyphenylalanine (DOPA, Y) residues in the mussel

88 ls of dopamine (DA) and its metabolites, 3,4-dihydroxyphenylalanine (DOPAC) and homovanillic acid (HV

89 mines significant to the fly including L-3,4-dihydroxyphenylalanine, dopamine, tyramine, and serotoni

90 This was achieved using [(18)F]fluoro-levo-dihydroxyphenylalanine dynamic positron emission tomogra

91 iorally effective dose of DA precursor l-3,4-dihydroxyphenylalanine effectively reversed these change

92 hesis capacity was measured by fluorine-18-l-dihydroxyphenylalanine (F-18-FDOPA) positron emission to

93 f locus coeruleus pigmented neurons, and 18F-dihydroxyphenylalanine (FDOPA) PET to assess putaminal d

94 of phenylalanine hydroxylase is critical for dihydroxyphenylalanine formation.

95 s can be trapped by added catechol or by the dihydroxyphenylalanine formed during turnover.

96 ly relevant cargos, nipecotic acid and l-3,4-dihydroxyphenylalanine (i.e., l-DOPA), were attached to

97 to catalyze the hydroxylation of tyrosine to dihydroxyphenylalanine in catecholamine biosynthesis.

98 es the hydroxylation of tyrosine to form 3,4-dihydroxyphenylalanine in the biosynthesis of the catech

99 Dopa (3,4-dihydroxyphenylalanine) is recognized as a key chemical

100 resents decarboxy-(E)-alpha,beta-dehydro-3,4-dihydroxyphenylalanine, is a potently antimicrobial octa

101 han, R(**) is dihydroxyarginine, Y(*) is 3,4-dihydroxyphenylalanine, K(*) is 5-hydroxylysine, and K(*

102 nt 1 established that DD mice treated with L-dihydroxyphenylalanine (L-dopa [LD]) perform similarly t

103 Here, we explore the evolution of l-3,4-dihydroxyphenylalanine (l-DOPA) 4,5-dioxygenase (DODA) e

104 ty in dopamine-deficient mice than did l-3,4-dihydroxyphenylalanine (l-dopa) administration, which pa

105 ty of one variant could be improved by l-3,4-dihydroxyphenylalanine (l-DOPA) administration; this hyp

106 nding non-canonical amino acids (NCAAs), 3,4-dihydroxyphenylalanine (L-DOPA) and (8-hydroxyquinolin-3

107 exaggerated rotational behavior induced by L-dihydroxyphenylalanine (L-DOPA) and contralateral sensor

108 ibe a simple one-pot method, employing l-3,4-dihydroxyphenylalanine (L-DOPA) as a reducing/capping re

109 ynthesized by hydroxylation of tyrosine to L-dihydroxyphenylalanine (L-Dopa) by tyrosine hydroxylase

110 The catechol group of 3,4-dihydroxyphenylalanine (L-DOPA) derived from L-tyrosine

111 eatment of Parkinson disease (PD) with L-3,4-dihydroxyphenylalanine (L-DOPA) dramatically relieves as

112 -) mice required daily administration of 3,4-dihydroxyphenylalanine (L-DOPA) for survival beyond 2 to

113 The application of L-3,4-dihydroxyphenylalanine (L-DOPA) increased the IPSC in Le

114 The dopamine precursor L-beta-3,4-dihydroxyphenylalanine (L-DOPA) inhibited cleavage of 35

115 The catecholamine precursor l-dihydroxyphenylalanine (L-DOPA) is the primary therapeut

116 aline; a synthetic dopamine precursor, L-3,4-dihydroxyphenylalanine (L-DOPA) methyl ester; a direct d

117 tropolymerization of dopamine (DA) and L-3,4-dihydroxyphenylalanine (L-DOPA) on carbon nano-onion (CN

118 SKF 82958 and the indirect DA agonist L-3,4-dihydroxyphenylalanine (L-DOPA) on the acoustic startle

119 tested in 7 aged rhesus monkeys using L-3,4-dihydroxyphenylalanine (L-dopa) or the selective dopamin

120 Although L-3,4-dihydroxyphenylalanine (L-DOPA) remains the reference tr

121 oss of midbrain dopaminergic neurons and 3,4-dihydroxyphenylalanine (L-DOPA) reversible behavioral de

122 er since its introduction 40 years ago l-3,4-dihydroxyphenylalanine (l-DOPA) therapy has retained its

123 of dyskinesia that result from chronic L-3,4-dihydroxyphenylalanine (L-DOPA) therapy.

124 Daily treatment of DD mice with L-3,4-dihydroxyphenylalanine (L-DOPA) transiently restores bra

125 physiology and dyskinesia from chronic L-3,4-dihydroxyphenylalanine (L-DOPA) treatment, but the physi

126 opamine D1 or D2 receptor agonists and l-3,4-dihydroxyphenylalanine (l-DOPA) was 3- to 13-fold greate

127 In the present investigation, L-3, 4-dihydroxyphenylalanine (L-DOPA) was conjugated on HMW PE

128 g" clinical practice that avoids using L-3,4-dihydroxyphenylalanine (L-DOPA), a dopamine precursor, i

129 L-3,4-dihydroxyphenylalanine (L-DOPA), a naturally occurring t

130 be achieved by daily administration of L-3,4-dihydroxyphenylalanine (L-dopa), a precursor of dopamine

131 lar oxygen to hydroxylate tyrosine to form L-dihydroxyphenylalanine (L-DOPA), and tetrahydrobiopterin

132 eated with the dopamine (DA) precursor l-3,4-dihydroxyphenylalanine (L-DOPA), but its prolonged use c

133 ng freely, and injected with 100 mg/kg l-3,4-dihydroxyphenylalanine (L-DOPA), engage in a behavior (a

134 istration of the antiparkinsonian drug l-3,4-dihydroxyphenylalanine (l-DOPA), is accompanied by activ

135 ignificantly less amounts of dopamine, l-3,4-dihydroxyphenylalanine (L-DOPA), salsolinol, and N-acety

136 L-3,4-Dihydroxyphenylalanine (L-DOPA), synthesized from L-tyro

137 as a structure putatively involved in L-3,4-dihydroxyphenylalanine (L-Dopa)-induced dyskinesia (LID)

138 of brain nuclei putatively involved in L-3,4-dihydroxyphenylalanine (L-DOPA)-induced dyskinesia (LID)

139 Furthermore, in a mouse model of L-3,4-dihydroxyphenylalanine (L-DOPA)-induced dyskinesia (LID)

140 isrupted in Parkinson's disease and in l-3,4-dihydroxyphenylalanine (l-DOPA)-induced dyskinesia (LID)

141 gonists have targeted PD patients with L-3,4-dihydroxyphenylalanine (L-DOPA)-induced dyskinesia (LID)

142 loped treatment complications known as L-3,4-dihydroxyphenylalanine (L-DOPA)-induced dyskinesia (LID)

143 L-3,4-dihydroxyphenylalanine (L-DOPA)-induced dyskinesia is an

144 incubated with the dopamine precursor, L-3,4-dihydroxyphenylalanine (L-DOPA).

145 s after exposure to the dopamine precursor L-dihydroxyphenylalanine (L-DOPA).

146 ine receptor agonists apomorphine and L-3, 4-dihydroxyphenylalanine (L-DOPA).

147 he 3-hydroxylation of tyrosine to form l-3,4-dihydroxyphenylalanine (l-DOPA).

148 hydroxyphenylacetaldehyde (DHPAA) from L-3,4-dihydroxyphenylalanine (L-DOPA).

149 be maintained by daily treatment with l-3,4-dihydroxyphenylalanine (L-dopa).

150 be synthesized by another pathway via l-3,4-dihydroxyphenylalanine (L-DOPA).

151 ne is restored by daily treatment with l-3-4-dihydroxyphenylalanine (l-dopa).

152 nless the animals were pretreated with l-3,4-dihydroxyphenylalanine (l-dopa).

153 inistration of the dopamine precursor, L-3,4-dihydroxyphenylalanine (L-dopa).

154 by administration of the tyrosinase product dihydroxyphenylalanine (l-dopa).

155 ey are rescued by daily treatment with L-3,4-dihydroxyphenylalanine (L-DOPA); each dose restores dopa

156 l dopamine (DA) replacement with Levodopa [L-dihydroxyphenylalanine (L-DOPA)] is the gold standard tr

157 receptors GPR43/GPR109A, and modulated L-3,4-dihydroxyphenylalanine levels and the abundance of T reg

158 l-3,4-dihydroxyphenylalanine-mediated dyskinesias were also si

159 Dopamine- and 3,4-dihydroxyphenylalanine-melanin products were identified

160 Ultraviolet-Vis absorbance spectra of L-3,4-dihydroxyphenylalanine-melanin solutions at different co

161 oduce dioxindolyl-L-alanine, kynurenine, 3,4-dihydroxyphenylalanine, N'-formylkynurenine, and 5-hydro

162 Analytes including L-3,4-dihydroxyphenylalanine, N-acetyl octopamine, N-acetyldop

163 ed after treatment with the catecholamines L-dihydroxyphenylalanine, norepinephrine, epinephrine, and

164 ion remains largely limited to the Dopa (3,4-dihydroxyphenylalanine) or catechol functionality, which

165 g using the dopamine precursor l-DOPA (l-3,4-dihydroxyphenylalanine) or dopamine receptor agonists re

166 gic analysis using hematoxylin and eosin and dihydroxyphenylalanine oxidase special stains.

167 osine hydroxylase activity of tyrosinase and dihydroxyphenylalanine oxidation drop rapidly, while DOP

168 ibited occasional large complexes containing dihydroxyphenylalanine-positive cisterna and 50 nm vesic

169 (18)F-fluoro-L-dihydroxyphenylalanine positron emission tomography (PET

170 Microdialysis and [(18)F]-fluoro-l-dihydroxyphenylalanine positron emission tomography iden

171 f HPS1 protein resulted in the deposition of dihydroxyphenylalanine reaction products (i.e., tyrosina

172 n cultured human RPE, KL increases the l-3,4-dihydroxyphenylalanine synthesis and inhibits vascular e

173 o[3,4-c]pyridin-5-one, increased DOPA (L-3,4-dihydroxyphenylalanine) synthesis 84% in the hippocampus

174 (spillovers) and regional plasma levels of L-dihydroxyphenylalanine (the immediate product of the rat

175 In the case of binding of dihydroxyphenylalanine, the decrease in affinity upon ph

176 L-3,4-dihydroxyphenylalanine, the immediate precursor of dopam

177 behaviors (dyskinesias) in response to l-3,4-dihydroxyphenylalanine, the principal treatment for Park

178 th Parkinson's disease receiving long-term l-dihydroxyphenylalanine therapy, the results of the prese

179 ine, norepinephrine, octopamine (OA), L-3, 4-dihydroxyphenylalanine, tyramine (TA), and serotonin as

180 igra and PC12 cell cultures by exposure to l-dihydroxyphenylalanine, which is rapidly converted to do